J
Jan A. Burger
Researcher at University of Texas MD Anderson Cancer Center
Publications - 543
Citations - 33028
Jan A. Burger is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Chronic lymphocytic leukemia & Ibrutinib. The author has an hindex of 83, co-authored 511 publications receiving 28306 citations. Previous affiliations of Jan A. Burger include University of Texas Health Science Center at Houston & University of Freiburg.
Papers
More filters
Journal ArticleDOI
Phase I and extension study of clofarabine plus cyclophosphamide in patients with relapsed/refractory acute lymphoblastic leukemia.
Stefan Faderl,Kumudha Balakrishnan,Deborah A. Thomas,Farhad Ravandi,Gautam Borthakur,Jan A. Burger,Alessandra Ferrajoli,Jorge E. Cortes,Susan O'Brien,Tapan M. Kadia,Jennie Feliu,William Plunkett,Varsha Gandhi,Hagop M. Kantarjian +13 more
TL;DR: The combination of clofarabine plus cyclophosphamide at the doses used in this study in a group of heavily pretreated patients with ALL is only moderately effective and other doses, alternative schedules, or a more favorable patient population may achieve better results.
Journal ArticleDOI
Phase II Study of Vorinostat in Combination with Idarubicin (Ida) and Cytarabine (ara-C) as Front Line Therapy in Acute Myelogenous Leukemia (AML) or Higher Risk Myelodysplastic Syndrome (MDS).
Guillermo Garcia-Manero,Francesco Paolo Tambaro,B. Nebiyou Bekele,Elias Jabbour,Farhad Ravandi,Hui Yang,Gautam Borthakur,Tapan M. Kadia,Jorge E. Cortes,Stefan Faderl,Marina Konopleva,Sherry Pierce,Jan A. Burger,Zeev Estrov,Susan O'Brien,Deborah A. Thomas,Willie Newsome,Hagop M. Kantarjian +17 more
TL;DR: A phase II study of vorinostat followed by Ida and ara-C in pts with AML or MDS, designed to stop early based on a composite endpoint and predefined stopping rules of progression free survival (PFS), toxicity and response rates compared to standard IdA and Ara-C (IA) combination at MD Anderson.
Journal ArticleDOI
Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
Nicholas J. Short,Hagop M. Kantarjian,Farhad Ravandi,Xuelin Huang,Nitin Jain,Koji Sasaki,Rita Khouri,Naval Daver,Naveen Pemmaraju,Joseph D. Khoury,Jeffrey L. Jorgensen,Yesid Alvarado,Marina Konopleva,Guillermo Garcia-Manero,Tapan M. Kadia,Musa Yilmaz,Gautam Borthakur,Jan A. Burger,Steven M. Kornblau,William G. Wierda,Courtney D. DiNardo,Alessandra Ferrajoli,Jovitta Jacob,Meagan Rostykus,Rebecca Garris,Marygrace Ward,Binru Huang,Corabelle Encarnacion,Christopher Loiselle,Susan O'Brien,Elias Jabbour +30 more
TL;DR: The combination of INO with reduced-intensity mini-hyper-CVD chemotherapy in older adults with newly diagnosed ALL is safe and highly effective and the addition of blinatumomab to this regimen may further improve outcomes.
Journal ArticleDOI
Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL): Focus on MRD Results
Nitin Jain,Michael J. Keating,Philip A. Thompson,Alessandra Ferrajoli,Jan A. Burger,Gautam Borthakur,Koichi Takahashi,Zeev Estrov,Koji Sasaki,Nathan Fowler,Tapan M. Kadia,Marina Konopleva,Yesid Alvarado,Musa Yilmaz,Courtney D. DiNardo,Prithviraj Bose,Maro Ohanian,Naveen Pemmaraju,Elias Jabbour,Rashmi Kanagal-Shamanna,Keyur P. Patel,Wei Wang,Jeffrey L. Jorgensen,Sa A. Wang,Naveen Garg,Xuemei Wang,Chongjuan Wei,Nichole Cruz,Ana Ayala,William Plunkett,Hagop M. Kantarjian,Varsha Gandhi,William G. Wierda +32 more
TL;DR: Jain et al. as discussed by the authors reported results of the first-line cohort of a phase II trial of combined IBR and VEN for patients with CLL with focus on MRD.
Journal ArticleDOI
Outcomes for patients with chronic lymphocytic leukemia and acute leukemia or myelodysplastic syndrome.
Francesco Paolo Tambaro,Guillermo Garcia-Manero,Susan O'Brien,Stefan Faderl,Alessandra Ferrajoli,Jan A. Burger,Sherry Pierce,Xuemei Wang,Kim Anh Do,Hagop M. Kantarjian,Michael J. Keating,William G. Wierda +11 more
TL;DR: Outcomes for patients with CLL subsequently diagnosed with AL or MDS were very poor; AL/MDS occurred without prior CLL treatment; shorter survival from MDS correlated with higher risk IPSS, poor-risk karyotype and increased number of prior C LL treatments.